(RMTI) Exclusive Long-Term Agreement With Baxter Over Hemodialysis Concentrates

Rockwell Receives $20MM Upfront Cash; $15MM Equity Investment; $10MM in Milestone Payments Tied to Manufacturing Expansion

WIXOM, Mich., Oct. 3, 2014  — Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it has signed an exclusive agreement with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (NYSE:BAX), to commercialize Rockwell’s hemodialysis concentrate product line in the U.S. and in select overseas markets.

Under the terms of the agreement, Baxter will become the exclusive distributor of Rockwell’s hemodialysis concentrate and ancillary products in the U.S. and selected foreign countries for an initial term of 10 years. Baxter can extend the agreement for two additional 5-year terms upon meeting certain sales targets, coupled with a $7.5 million payment related to the first extension. Baxter will purchase products from Rockwell at a pre-determined gross margin-based price per unit and is required to meet minimum annual purchase levels in order to retain their exclusive rights. Baxter will leverage Rockwell’s unique distribution operations in order to provide specialized customer and delivery service for concentrates, covering Rockwell’s costs for these services. Rockwell will retain sales, marketing and distribution rights for its hemodialysis concentrate products in certain foreign countries in which it has an established commercial presence.

In consideration for the exclusive commercialization rights, Baxter will pay Rockwell $20 million in cash. Baxter will also purchase $15 million of Rockwell common stock. The investment in Rockwell shares is being made at a price per share equal to the average closing price of RMTI shares over the last 12 months (or $11.39 per share). Rockwell is eligible for milestone payments totaling $10 million related to the expansion of its manufacturing capabilities to serve customers across the U.S.

“This long-term, strategic supply and distribution agreement enables Rockwell to expand and accelerate our hemodialysis concentrate business, while we continue to strategically build our drug pharma business in the U.S. and globally,” stated Robert L. Chioini, Founder, Chairman and CEO of Rockwell.  “We are excited to be partnering with Baxter, a global market leader who has a proven track record in the field of dialysis and renal products. This agreement benefits dialysis patients and service providers by expanding access to our market leading products in new territories, while reducing future risk.”

Jill Schaaf, Corporate Vice President and President of Baxter’s Renal business, added, “Baxter remains committed to addressing the needs of patients and healthcare providers with a comprehensive range of therapeutic options across home, in-center and hospital settings.  This partnership enhances Baxter’s product portfolio with the addition of Rockwell’s high-quality hemodialysis concentrate products.”

Conference Call Information

Rockwell Medical will be hosting a conference call to discuss the agreement on Friday, October 3, 2014 at 8:30am ET. Investors are encouraged to call a few minutes in advance at (877) 383-7438, or for international callers (678) 894-3975, passcode # 14838823 or to listen to the call via webcast at the Rockwell Medical IR web page: http://ir.rockwellmed.com/

About Rockwell Medical

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.

Rockwell’s lead investigational drug Triferic is currently under NDA review by the FDA for the treatment of iron replacement/maintenance in dialysis patients, with a PDUFA date of January 24, 2015. Triferic delivers iron to the bone marrow of dialysis patients in a non-invasive, physiologic manner during their regular dialysis treatment, using dialysate as the delivery mechanism. In completed clinical trials to date, Triferic has demonstrated that it may safely and effectively deliver sufficient iron to the bone marrow, maintain hemoglobin and not increase iron stores (ferritin), while significantly reducing ESA dose. Triferic has successfully completed the efficacy trials of its Phase 3 clinical study program (CRUISE-1 and CRUISE-2).

Rockwell is preparing to launch its FDA approved generic drug Calcitriol, to treat secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in in the U.S. dialysis market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three manufacturing/distribution facilities located in the U.S. and its operating infrastructure is a ready-made sales and distribution channel that is able to provide seamless integration into the commercial market for its drug product Calcitriol, and Triferic upon FDA market approval.

Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information. For a demonstration of the Triferic unique mechanism of action in delivering iron via dialysate, please view the animation video at http://www.rockwellmed.com/collateral/documents/english-us/mode-of-action.html.

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to launch Calcitriol and Triferic following FDA approval. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Triferic^™ is a trademark of Rockwell Medical, Inc. / CitraPure^® is a registered trademark of Rockwell Medical, Inc.

CONTACT: Michael Rice, Investor Relations; 646-597-6979

(BION) City Council of Perry, Florida Unanimously Approves to Continue Funding, $5M Balance

(RSH) Announces Milestone In Recapitalization Process

Investors Acquire ABL Facility from GE Capital $120 Million Investment Expected to be Converted into Equity Rights Offering to Current Shareholders Planned at Conversion Price

FORT WORTH, Texas, Oct. 3, 2014 — RadioShack Corporation (NYSE: RSH) today announced that it has entered into definitive agreements to restructure a portion of its existing debt, providing additional near-term liquidity and serving as a first step in a stronger foundation for the Company’s continued business transformation.

Standard General LP and certain other investors have replaced GE Capital as lead lender under RadioShack’s senior secured asset based credit facility (“ABL Facility”) which will allow immediate access to additional liquidity.  Other investors, including RadioShack shareholders Standard General and Litespeed Management LLC, are providing $120 million to be used to cash collateralize letters of credit for the Company.  In the coming months, this $120 million is expected to be converted into equity.  Current shareholders will have the opportunity to participate in a rights offering at same conversion price.

“We are pleased to complete this important step, which we believe positions us to continue to progress our operational turnaround,” said Joe Magnacca, RadioShack’s chief executive officer.  “We recognize that we will need to address constraints under our existing term loan in order to undertake a store base consolidation program and pursue other measures to reduce our cost structure.  This amended ABL Facility provides time to pursue a longer-term restructuring.  To that end, we are in constructive discussions with our term lenders, led by Salus Capital, toward additional steps to recapitalize RadioShack.

“We look forward to continuing to serve our customers with differentiated products and an upgraded shopping experience as we move into the Holiday season.”

Today’s agreements include two key elements:

• ABL Facility – Standard General and certain other investors have acquired the loans and agreed to changes affecting the credit availability under RadioShack’s existing ABL Facility.  As a result, RadioShack believes that it will have sufficient credit capacity under the ABL Facility to fund its inventory build for the Holiday season.  Because borrowing availability under the amended ABL Facility changes in March 2015, the Company expects to seek to refinance the facility by that time.  In addition, the amended ABL Facility will be required to be refinanced if the rights offering described below is not completed by March 15, 2015.
• New equity – The $120 million investment is expected to be converted into equity securities representing (together with related fees payable in equity securities) not less than 50% of the Company’s outstanding equity securities upon satisfaction of certain conditions.  These conditions include the modification of a supplier contract, at least $100 million of available cash and borrowing capacity at January 15, 2015, development of a fiscal 2016 plan satisfying certain requirements and the completion of a rights offering to existing RadioShack shareholders to purchase equity securities at a price of $0.40 per common share equivalent.

The percentage of equity securities that Standard General and other investors will own as a result of this transaction will depend upon the level of participation, if any, of existing shareholders in the rights offering.  If no shares were purchased in the rights offering, existing shareholders would own 20% of RadioShack’s equity securities.  The voting rights of any person or group acquiring equity securities in the transaction would be limited to 34.9% of the total voting power of the Company’s voting stock so long as greater voting power would accelerate Company debt.

If the $120 million investment is converted into equity, the Board will be reconstituted to consist of the Company’s CEO, two independent directors selected by RadioShack and four individuals nominated by Standard General.  The new directors must be approved by the Company’s corporate governance committee.  At least two of these directors must be independent.

RadioShack intends to initiate the rights offering late this year or in early 2015.  There can be no assurance that the rights offering will be completed or that the other conditions to the equity conversion will be satisfied, nor can the Company be certain that it will be able to refinance borrowings under the amended ABL Facility by March 2015.

NYSE EXEMPTION

The stock issuances described above would normally require approval of RadioShack’s shareholders pursuant to the Shareholder Approval Policy of the New York Stock Exchange (the “Exchange”). The audit and compliance committee of RadioShack’s Board of Directors determined that the delay that would result from securing shareholder approval prior to the completion of these stock issuances would seriously jeopardize the financial viability of RadioShack. Because of that determination, the audit and compliance committee, pursuant to an exception provided in the Exchange’s shareholder approval policy, expressly approved RadioShack’s omission to seek the shareholder approval that would otherwise have been required under that policy. The Exchange has accepted the Company’s application of the exception.

In conjunction with the rights offering, RadioShack intends to initially issue equity securities that would be convertible, subject to the satisfaction of all applicable conditions, into at least 400 million shares (and up to 700 million shares) of common stock. In reliance on the Exchange’s shareholder approval exception, RadioShack will notify its shareholders of its intention to issue the shares without seeking their approval at least ten days prior to the issuance of the shares.

CERTAIN LEGAL MATTERS

The securities to be offered in the rights offering will be offered pursuant to a registration statement to be filed with the SEC and a related prospectus. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of, such shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

This press release does not set forth all of the terms and conditions of the issuances of shares and other transactions contemplated by the recapitalization agreements described above.  The material contracts relating to these matters will be filed by the Company with the SEC.

This press release contains information about a pending transaction, and there can be no assurance that this transaction will be completed.

ADVISORS

RadioShack’s financial advisor is Peter J. Solomon Company and its legal counsel is Jones Day.  Lazard Feres and Co. is acting as the financial advisor to RadioShack’s Board of Directors.  Debevoise & Plimpton LLP is legal counsel to Standard General.  Blank Rome LLP advised investors of the ABL Facility.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, as referenced in the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management’s current views and projections regarding economic conditions, the retail industry environment and RadioShack’s performance. These statements can be identified by the fact that they include words like “anticipate,” “believe,” “estimate,” “expect,” “intend,” “project,” “guidance,” “plan,” “outlook” and other words with similar meaning. We specifically disclaim any duty to update any of the information set forth in this press release, including any forward-looking statements. These statements involve a number of risks and uncertainties that could cause our actual results to differ materially from the results discussed in our forward-looking statements, including the risk that the transactions described herein may not be consummated, including a failure to satisfy each of the conditions to the conversion of the $120 million investment into equity securities of the Company, the refinancing of the amended ABL Facility, the completion of the rights offering and the continued availability of working capital financing.  The failure to complete these transactions would have a material adverse effect on RadioShack’s liquidity and financial viability. Additional factors that could cause our actual results to differ materially from the results discussed in our forward-looking statements include, but are not limited to, our ability to execute and the effectiveness of our initiatives, including our strategic turnaround plan and our proposed store closure program; the underperformance or loss of certain of our important vendors, such as our wireless carrier providers, or breaches by them of our agreements with them; difficulties associated with our transition to an outsourced arrangement for the production of products we previously manufactured at our Chinese manufacturing plant; an adverse impact on our sales or profitability due to our transition to such an outsourced arrangement; an adverse impact on our sales or profitability due to changes wireless carrier providers make to their customer credit requirements, frequency of upgrade eligibility, or other operational matters, and the timing, completeness and accuracy of information we receive about such changes; a decline in our gross margin due to customer demand for lower margin mobile devices, such as smartphones and tablets; overall sales performance; economic conditions; product demand; expense levels; competitive activity; interest rates; changes in RadioShack’s financial condition; availability of products and services and other risks associated with RadioShack’s vendors and service providers; the regulatory environment; and other factors affecting the retail category in general. Additional information regarding these and other factors is included in RadioShack’s filings with the SEC, including its most recent Annual Report on Form 10-K for the year ended Dec. 31, 2013.

ABOUT RADIOSHACK CORPORATION

RadioShack (NYSE: RSH) is a leading retailer focused on connecting customers with personalized solutions and discovering what’s possible through the latest in consumer technology.  The company’s updated product assortment incorporates national brands, industry-leading private brand products and in-demand mobile devices from a wide selection of wireless carriers.  Customers can shop top brands in headphones and speakers, wearable technology, smart toys and DIY supplies, connected home, power accessories and home entertainment at www.radioshack.com or in store.  RadioShack’s global retail network includes more than 4,300 company-operated stores in the United States and Mexico and more than 1,200 dealer franchise stores in 25 countries.  RadioShack employs approximately 27,000 knowledgeable associates globally to help customers find their technology solutions.  For more information on RadioShack Corporation, please visit www.radioshackcorporation.com.  RadioShack® is a registered trademark licensed by RadioShack Corporation.

Analysts and Investors Contact: Investor Relations, +1-817-415-3400,
Investor.Relations@RadioShack.com,
or
News Media Contact: Media Relations, +1-817-415-3300,
Media.Relations@RadioShack.com

(BKRL) Plans to Acquire Bank Reale

BEO Bancorp (OTCBB:BEOB) and its subsidiary, Bank of Eastern Oregon, announced today that they have entered into a definitive agreement to acquire Bank Reale (OTCBB:BKRL). The combined banking operation will have about 120 employees with total assets of nearly $350 million.

Jeff Bailey, President and CEO for Bank of Eastern Oregon, referred to the common philosophies shared by BEO and Bank Reale: “Our goal is to expand upon and execute the original vision of Bank Reale’s founders: To provide unequaled customer service and serve the banking needs of the local Pasco community as well as the outlying rural areas of the Columbia Basin. Bank of Eastern Oregon has served rural eastern Oregon for nearly 70 years and we are excited to expand our footprint and bring our style of banking to the region. Bank Reale has a talented group of employees that we look forward to bringing into our banking family.”

Bank of Eastern Oregon, based in Heppner, Oregon, was founded in 1945 as Gilliam County Bank in Arlington, Oregon. Since that time, the bank has expanded to 12 branches and five loan production offices located in 11 eastern Oregon counties. The bank was founded by farmers and ranchers and views agricultural lending as key to its historical, as well as future, success.

Fred Zack, Interim President and CFO for Bank Reale, said, “Both institutions have similar cultures and philosophies when it comes to customer service and to the employees who make great customer service happen. The consolidation of Bank Reale into Bank of Eastern Oregon is a natural fit for both in other ways as well. We will now have access to their financial resources and added services for our existing and future customers, and they now have a platform for long-term growth in the Tri-Cities and the Columbia Basin in harmony with their core belief in supporting the communities and customers they serve.”

“The banking world has seen significant changes over the past five years in terms of consolidation and economies of scale. The acquisition of Bank Reale provides Bank of Eastern Oregon an excellent access to Pasco and rural southeastern Washington,” said Bailey.

The transaction is expected to close during first quarter 2015, following approval by Bank Reale shareholders and final regulatory approval. The terms of the transaction are not being disclosed but involve a combination of cash and stock. Upon closing of the acquisition, the Pasco facility will operate as a branch of Bank of Eastern Oregon, doing business as Bank of Eastern Washington. Commerce Street Capital, L.L.C., and LC Financial Advisors, L.L.C., served as financial advisors to Bank of Eastern Oregon. McAdams Wright Ragen, Inc. served as financial advisor to Bank Reale.

About BEO Bancorp

BEO Bancorp is the holding company for Bank of Eastern Oregon, which operates 12 branches and five loan production offices in 11 eastern Oregon counties. Branches are located in Arlington, Ione, Heppner, Condon, Irrigon, Boardman, Burns, John Day, Prairie City, Fossil, Moro, and Enterprise; loan production offices are located in Hermiston, Ontario, Island City, Pendleton, and Lakeview. Bank of Eastern Oregon also operates a mortgage division. The bank’s website is www.beobank.com.

(AVOT) Upgrades to OTC Pink Current Information Tier

LAS VEGAS, NV / October 3, 2014 / American Video Teleconferencing Corp. (PINKSHEETS:AVOT) announced today that it has moved up to OTC Pink Current Information Tier on OTC Markets (www.otcmarkets.com) after filing material company information and recent financials toward overall transparency, accessibility and market integrity.

“In addition to being very pleased to have reached the highest tier in the OTC Pink Markets” said Kenneth Bosket, President of American Video Teleconferencing Corp. “We are looking forward to continuing our enhanced transparency with shareholders”

American Video Teleconferencing Corp., (OTCPink:AVOT) most recent communication with OTC Markets Issuer Services stated; “We have finished processing your disclosure, attorney letter, and attorney letter agreement for the period ending June 30, 2014 and December 31, 2012/2013. Your company will be moved to the OTC Pink Current Information tier before the next market open”.

About American Video Teleconferencing Corp.

American Video Teleconferencing Corp., has two (2) sub-company operations known as, Roxzu and AVOtube. Roxzu is developing into a voucher/coupon distribution mobile app accessible by smart phones, iPhones, androids and computers online, as well as being an online national business directory. AVOtube www.avotube.com is a video-sharing hosting service that allows user to upload videos to share for exposure, branding, marketing and advertising. For more information visit: www.avotconf.com.

Forward Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new business opportunities and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the most recent fiscal year and quarterly reports, as well as other periodic reports filed from time-to-time.

Contact:

Kenneth Bosket, President
702 998-3490
ken@avotconf.com

(MMMW) Frankenstein Solar Power Monster To Cut Cost of Solar Energy Over 20 Percent

WORCESTER, Mass. / October 03, 2014 / Mass Megawatts Wind Power, Inc. (OTCQB: MMMW) reports it will introduce to the world the Frankenstein Solar Power Monster, a new solar power tracking system on October 27. Mass Megawatts has significantly reduced the cost of solar energy with its patent-pending, Solar Power Tracking System (STS) through the use of an advanced design with fewer electrical components and moving parts. With near-zero dynamic and static load requirements, the solar-tracker avoids most of the torque requiring costly components. It reduces the need for large drivetrains and motors that traditional systems utilize.

The STS provides an efficient way to maximize the generation of solar power and gives Mass Megawatts a distinct cost advantage in the solar power industry. Product and sales inquiries have continued to indicate strong demand for the STS, and commercial production is anticipated to being in the next few months.

The Mass Megawatts STS is a complete solar-power system designed to automatically adjust the position of its solar panels throughout the day to receive an optimal level of direct sunlight. Unlike other solar tracking technologies, the Mass Megawatts STS utilizes a low-cost structure that adds stability to the overall system while improving energy production levels up to 28%.

Starting at 6.25 kW rated units, a Mass Megawatts STS system is appropriate for ground-level, residential and business sites, as well as, commercial, roof-top installations. Mass Megawatts coordinates all aspects of system delivery, including permitting, installation, and working to obtain any available tax incentives. They monitor the performance of each system, and provide a full, performance guarantee.

With its patent pending, Solar Tracking System, Wind Electric-Power Generation system, a new retail sales business, only approximately 50 million shares issued and outstanding, and very little debt, Mass Megawatts believes it is well positioned to ramp-up production in the shorter term while expanding its infrastructure to support mass-production goals in the longer term.

This press release contains forward-looking statements that could be affected by risks and uncertainties. Among the factors that could cause actual events to differ materially from those indicated herein are: the failure of Mass Megawatts Wind Power, also known as Mass Megawatts Windpower, to achieve or maintain necessary zoning approvals with respect to the location of its power developments; the ability to remain competitive; to finance the marketing and sales of its electricity; general economic conditions; and other risk factors detailed in periodic reports filed by Mass Megawatts Wind Power

Product information and sales inquiries can be made through the company’s contact page at

www.massmegawatts.com

Contact Information:
Mass Megawatts Wind Power, Inc.
(508) 751-5432

(PVSP) Goes Virtual

WHITE PLAINS, N.Y., Oct. 3, 2014  — Pervasip Corp. (OTC Pink: PVSP) announced that it entered into an agreement to sell and license back its award-winning VoIP technology platform.

Pervasip’s Chief Executive Officer, Paul Riss, stated, “We have restructured our operations by selling a copy of the software we developed to one of our customers and exchanging fixed operating costs for variable costs, so that we can continue to be a mobile VoIP company without incurring expensive overhead.  We plan to operate in the cloud, and keep our monthly recurring costs as low as possible.”

“We believe in the power of our cloud-based technology, but without having the financing that we needed to grow our customer base, it made more sense for us to extract value from our software to help us move forward,” continued Riss.  “Instead of paying fixed salaries and fixed costs for collocation facilities and circuits, we are changing our business model, so that all our costs of providing mobile VoIP services, including technical support and customer service, are a percentage of our revenue dollar.”

Pervasip agreed to receive 40 million shares of common stock of Valuesetters, Inc. to complete this transaction.  Pervasip continues to own its VoIP technology, but Valuesetters is also an owner and is operating the software and providing technical support and customer service for Pervasip.

About Pervasip

Pervasip delivers mobile VoIP and video telephone service anywhere in the world that has a stable broadband connection.  In addition to international telephone numbers from 57 countries for mobile phone users, with unlimited inbound calling, it offers several international outbound calling plans, including some of the lowest rates to international mobile phones.

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

FOR FURTHER INFORMATION:

AT PERVASIP:
Paul H. Riss
Chief Executive Officer
Ph:  914-750-9339
phriss@pervasip.com

(WFMC) & P2Pxtreme Sign 22 million contract with Digital taxi Tops LLC

Park Ridge, IL / Ocotber 02, 2014 / Woodman Holdings “Wham Inc” and P2P are excited to announce that P2P has formally finalized and successfully consummated the 5-year contract with Digital Taxi Tops, LLC. (an Ad-Technology division of BELL TRANS, Inc.), valued at the minimum of $22M including a royalty-type residual revenue stream per vehicle per each month; successfully reaching another investment objective milestone outlined in its mission statement of the investment portfolio. With a minimum of two other major US Taxi Operators interested in coming on board, the overall value of the project, including all contractual residual-revenue components, is estimated to exceed $45M during its initial contract term of 5 years.

The mass production for the digital taxi top displays has begun at the factory in South Korea last week with the first shipment targeted to arrive – just in time for the Christmas Holiday rush in Las Vegas, Nevada.

S-1 Registration Filing:

Woodman Holdings is pleased to announce it has reach another milestone of moving forward in becoming a fully reporting registered SEC company by contracting the services of Securities Compliance Group, Ltd. (legal counsel) on September 18th, 2014.

The engagement agreement sets forth the terms and conditions of the attorney-client representation rights and responsibilities prepared by the Counsel. The objectives of the legal representation contemplated herein is to successfully provide the corporation with finance, securities and tax and legal services with regard to filing of a registration of the Client’s Securities on Form S-1 and capital financing of Client, as more particularly described in the proposal and agreement.

Upon completion of the Form S-1 registration and funding, Wham Inc. intends to seek a listing on a major exchange. Through this agreement, Wham Inc. continues to differentiate itself from the other companies listed on the OTC markets and gains it’s proper consideration that escalates it’s process of growth and development.

Forward-Looking Statement

This Press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on the Company’s current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.

Contacts:

Wham Inc, Investors Relations Department

contact us via email at: investorrelations@whamcorp.us

or for all general inquiries

contact us via email at: info@whamcorp.us

(OREO) Cancels Majority of Its Stock

HOUSTON, Oct. 2, 2014  — American Liberty Petroleum Corp. (OTCBB:OREO) announces today that it will cancel over sixty three percent (63%) of the company’s outstanding Common Stock shares. Three major shareholders have signed an agreement to exchange stock certificates, owned by them and already submitted to the company’s CFO, for one million (1,000,000) Common Stock shares each – for a total of over sixty eight million (68,469,993) Common Stock shares being cancelled and three million (3,000,000) being issued.

“These shareholders, including the Chief Executive Officer prior to Mr. Rhodes, believe that our current management team and its plan focusing on enhancing shareholder value will bring major benefits to our shareholders,” said Steven M. Plumb, American Liberty Petroleum Corp.’s Chief Financial Officer. “With 107,389,051 Common Stock shares outstanding as of the filing of our last 10Q, we are cancelling over sixty three percent (63%) of the outstanding Common Stock shares.”

The previously disclosed letter of intent for acquisition of Avant Diagnostics Inc. contemplates a closing date by October 1^st, 2014, based upon successful conclusion of due diligence, which is ongoing by both parties. The parties have signed an amended letter of intent providing for a later closing, October 31, after Avant Diagnostics Inc. submits a PCAOB audit to the company as part of the due diligence.

Shareholders should also note that Mr. Hunter M.A. Carr no longer has any position nor ownership in American Liberty Petroleum Corp. The Board of Directors accepted Mr. Carr’s resignation as Chairman on August 30, 2014.

About American Liberty Petroleum Corp.

American Liberty Petroleum Corp. (‘OREO’, http://americanlibertypetroleum.com/) is a fully reporting, development stage publicly traded company seeking acquisitions in the Gulf Coast oil & gas services business segment. OREO’s current management team, Robert C. Rhodes (CEO) and Steven M. Plumb (CFO), are actively involved in the search for acquisitions.

About Avant Diagnostics Inc.

Avant Diagnostics, Inc. (‘Avant’, http://avantdiagnostics.com) is a medical technology company based on the completion of the human genome sequencing project. Avant is developing specialized tests that are cutting edge in medical diagnostic testing and the OvaDx® Pre-Symptomatic Ovarian Cancer Screening Test is a leading breakthrough in commercializing these tests.

Genetic research is increasingly focused on identifying the variations of the specific genes in the genome. These variations are what define individual characteristics, including disease states or a statistical propensity for disease. The implications are far-reaching and impact not only the research community, but also the individual patients and the medical providers. Diagnostic tests that detect diseases very early in their progression will provide options for earlier treatments that may improve the patient’s quality of life and prognosis by delaying or preventing disease progression or even death. Medical providers will incur major cost savings by avoiding costly late stage disease treatments.

Safe Harbor

The statements in this press release that relate to American Liberty Petroleum Corp.’s expectations with regard to the future impact on American Liberty Petroleum Corp.’s results from new products and services in development, including any planned acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements might not occur. American Liberty Petroleum Corp. undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in American Liberty Petroleum Corp.’s plans or expectations.

CONTACT: Investor Contact
         Robert C. Rhodes
         American Liberty Petroleum Corp.
         investors@americanlibertypetroleum.com

         Steven Scott or Gregg Linn
         Avant Diagnostics, Inc.
         investors@avantdiagnostics.com

(OMAG) Signs Multi-Billion Dollar Agreement With Oman

NEW YORK, Oct. 2, 2014  — Omagine, Inc. (OTCQB:OMAG) today announced that its 60% owned subsidiary, Omagine LLC has signed a Development Agreement (“DA”) with the Government of the Sultanate of Oman (“Oman”).

Omagine, Inc. (the “Company”) organized Omagine LLC under the laws of Oman to design, develop, own and operate a tourism and real-estate development project in Oman named the Omagine Project. The Omagine Project is estimated to cost approximately $2.5 billion to design, develop and construct.

The Omagine Project is planned to be an integration of cultural, entertainment and residential components, including: hotels, commercial buildings, retail establishments and more than two thousand residences to be developed for sale. It will be developed on one million square meters (245 acres) of beachfront land (the “Omagine Site”) facing the Gulf of Oman just west of the capital city of Muscat and approximately six miles from Muscat International Airport.

Omagine LLC owns the Omagine Project which, over the next several years, is projected to generate exceptional cash flow to the Company and the other Omagine LLC shareholders. The Company owns 60% of Omagine LLC.

The other Omagine LLC shareholders are:

i. the office of Royal Court Affairs (“RCA”), which owns 25%, and

ii. two subsidiaries of Consolidated Contractors International Company, SAL (“CCIC”), which collectively own 15%.

The Company, RCA and the two CCIC subsidiaries are parties to a legally binding Shareholder Agreement which, among other things, provides for:

i. initially capitalizing Omagine LLC at 150,000 Omani Rials [$390,000], and

ii. increasing Omagine LLC’s capital to 26,988,125 Omani Rials [$70,169,125] within a 6 to 12 month period following the signing of the Development Agreement, and

iii. a payment-in-kind investment of the land constituting the Omagine Site (the “PIK”).

The value of the PIK investment will equal the value to Omagine LLC of the approximately 245 acres of beachfront land constituting the Omagine Site which His Majesty the Sultan owned and transferred to the Government for the specific purpose of developing it into the Omagine Project.

The value of the PIK will be determined by a professional valuation expert in accordance with Omani law and with the concurrence of Omagine LLC’s independent auditor, Deloitte & Touche, (M.E.) & Co. LLC. The value of the land constituting the Omagine Site is conservatively but informally estimated by local real-estate brokers to be in excess of $700 million.

The legally binding contract between the Government and Omagine LLC governing the design, development, construction, management and ownership of the Omagine Project and the use and sale by Omagine LLC of the land constituting the Omagine Site is the Development Agreement which the Government and Omagine LLC signed on October 2, 2014.

“We are tremendously pleased with today’s signing of the Development Agreement and are anxious to now begin the development of the Omagine Project,” said the Company’s president, Frank J. Drohan.

Drohan continued, “Our mission is to develop, own and operate innovative tourism projects with components that are thematically imbued with culturally aware, historically faithful, and scientifically accurate entertainment experiences. We design the tourism elements to provide modern, stylish and entertaining experiences while highlighting the world’s great cultures, art, music, heritage, science and philosophy. We expect the Omagine Project to be the archetype for our future projects in the Middle East and North Africa.”

About the office of Royal Court Affairs.

The office of Royal Court Affairs (“RCA”) is an Omani organization representing the interests of His Majesty, Sultan Qaboos bin Said, the ruler of Oman.

About Consolidated Contractors.

Consolidated Contractors International Company, SAL (“CCIC”) is a multi-national company headquartered in Athens, Greece. In 2012 CCIC had 5.4 billion dollars in revenue, 126,000 employees worldwide and operating subsidiaries in, among other places, every country in the Middle East and North Africa.

About Omagine, Inc.

Omagine, Inc. is a publicly traded company (Stock Symbol: OMAG). The Company conducts all of its real-estate development, tourism and entertainment business activities through either its 60% owned subsidiary Omagine LLC or its 100% owned subsidiary Journey of Light, Inc. The Company is focused on real-estate, entertainment and hospitality opportunities in the Middle East and North Africa (the “MENA Region”) which is one of the fastest growing tourist destinations in the world.

Governments in the MENA Region are seeking to diversify their economies and create employment for their citizens via the development of tourism destination projects. It is the Company’s opinion that this governmental strategic vision combined with the enormous financial resources in the MENA Region will continue to present superb development opportunities. The Company presently focuses the majority of its efforts on the business of Omagine LLC and specifically on the Omagine Project.

Investors or interested parties may visit Omagine’s website at www.omagine.com for more information about the Company or http://agoracom.com/ir/omagine which is the Company’s investor relations website.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, may be deemed to be forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of Omagine, Inc. can be found in the filings of Omagine, Inc. with the United States Securities and Exchange Commission.

CONTACT: Omagine, Inc.
         Corporate Inquiries
         Charles P. Kuczynski, Vice-President
         (212) 563-4141
         charles.kuczynski@omagine.com

(HKUP) Social Continues Its Growth, Exceeding 89,000 Downloads for September

Company Posts 7th Consecutive Month of Increased User Growth

(CALA) Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2014  — Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company, today announced the pricing of its initial public offering of 8,000,000 shares of common stock at a price of $10.00 per share. The common stock of Calithera Biosciences, Inc. has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol “CALA” on October 2, 2014. All of the common stock is being offered by Calithera Biosciences, Inc. In addition, Calithera Biosciences, Inc. has granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of common stock.

Citigroup and Leerink Partners are acting as joint book-running managers for the offering. Wells Fargo Securities and JMP Securities are acting as co-managers for the offering.

The offering will be made only by means of a prospectus. Copies of the prospectus related to the offering may be obtained, when available, from Citigroup Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, by email at prospectus@citi.com or by telephone at (800) 831-9146 or from Leerink Partners LLC, Attention:  Syndicate Department, One Federal Street, 37^th Floor, Boston, MA, 02110, by email at syndicate@leerink.com, or by telephone at (800) 808-7525, ext. 4814.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and declared effective on October 1, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Calithera Biosciences

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.

CONTACT: Investor Contact:
         Jennifer McNealey
         Calithera
         ir@Calithera.com
         650-870-1071

         Media Contact:
         BCC Partners
         Karen L. Bergman or
         Michelle Corral
         kbergman@bccpartners.com
         650.575.1509
         mcorral@bccpartners.com
         415.794.8662

(ARDX) Positive Results Phase 2b Clinical Evaluating Tenapanor in IBS-C Patients

— Primary endpoint was met for 50 mg twice daily dosing —

FREMONT, Calif., Oct. 1, 2014 — Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C).  Results from this study demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo. At the 50 mg dose, the study met its primary efficacy endpoint of an increase in the complete spontaneous bowel movement (CSBM) responder rate. Most secondary endpoints, including abdominal pain and other abdominal and IBS-C symptoms, demonstrated clinically meaningful improvements. Tenapanor was well-tolerated, and the safety results were consistent with those observed in previous tenapanor trials.

“We are pleased to see that tenapanor continues to demonstrate the degree of activity that was shown in the Phase 2a clinical trial for IBS-C,” said Mike Raab, President and CEO of Ardelyx. “We are excited about the potential for tenapanor in IBS-C.  We will work with our partner, AstraZeneca, to determine the best approach for the development of tenapanor in IBS-C and the renal indications that we are evaluating.”

“The magnitude of the response to tenapanor in this trial, combined with the fact that the drug was well-tolerated, with only a modest incidence of diarrhea is remarkable.  In addition, of those subjects who were administered 50 milligrams of tenapanor twice a day, over 65 percent responded that they were ‘quite satisfied’ or ‘very satisfied’ with tenapanor versus about 38 percent with placebo, a result that was also statistically significant,” said David Rosenbaum, Ph.D., Ardelyx’s Vice President of Drug Development.

Tenapanor, a minimally-absorbed inhibitor of the intestinal sodium transporter NHE3, has demonstrated the ability to reduce the absorption of dietary sodium and phosphate.  Ardelyx licensed tenapanor to AstraZeneca in October 2012.  In addition to IBS-C, Ardelyx and AstraZeneca are evaluating tenapanor for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) in an ongoing Phase 2b study, and in an ongoing Phase 2a study, tenapanor is being evaluated for its effect on markers of kidney disease and fluid status in patients with chronic kidney disease (CKD).

The Phase 2b Clinical Trial

The clinical trial was a Phase 2b, randomized, double blind, placebo-controlled, multi-center study to evaluate the safety and efficacy of three dose levels of tenapanor in 371 subjects with IBS-C as defined by the Rome III criteria and who had active disease as determined during a two-week screening period. Subjects who qualified and who were randomized into the study received 5, 20, or 50 mg of tenapanor or placebo twice daily for 12 consecutive weeks. At the end of this treatment period, subjects were followed for an additional 4 weeks. The primary endpoint, overall CSBM responder rate, was achieved in 60.7 percent of patients receiving tenapanor 50 mg twice daily versus 33.7  percent receiving placebo (p<0.001).  A responder was defined as a patient who had an increase of greater than or equal to one CSBM from baseline during 6 out of 12 weeks.  The results are reported on an intent-to-treat basis.

The overall responder rate, or dual composite endpoint percent, was achieved in 50 percent of patients receiving tenapanor 50 mg twice daily versus 23.6 percent receiving placebo (p<0.001).  An overall responder was defined as a patient who was an overall CSBM responder and who experienced at least a 30 percent decrease in abdominal pain from baseline in the same week for 6 of 12 weeks.

Most secondary endpoints measured also demonstrated significant improvements for patients receiving 50 mg tenapanor twice daily compared to placebo-treated patients.

A dose response relationship among all doses was observed in the primary endpoint, as well as in most secondary endpoints, although statistical significance was not achieved at the 5 mg or 20 mg doses.  Additionally, the activity of tenapanor was maintained throughout the entire 12-week treatment period.

Tenapanor was well-tolerated in these patients, and the safety results were consistent with those observed in previous tenapanor trials. The most common adverse events at 50 mg twice daily (greater than or equal to 5 percent) that occurred more frequently in tenapanor-treated patients compared to placebo-treated patients were diarrhea at 11.2 percent vs. 0 percent, and urinary tract infections at 5.6 percent vs. 4.4 percent.  Overall rates of discontinuation due to adverse events were 4.5 percent for the tenapanor-treated patients (50 mg twice daily) and 3.3 percent for the placebo-treated patients.  Based on the analysis of plasma samples tested as part of the study, the minimally systemic nature of tenapanor was confirmed. The findings of the clinical study are expected to be presented in an appropriate peer-reviewed forum.

IBS-C

IBS-C is a gastrointestinal disorder in which abdominal pain or discomfort is associated with constipation, significantly affecting health and quality of life. It is unknown what causes IBS-C. There is no specific test or biomarker for IBS-C and therefore, its presence is diagnosed by symptoms and by eliminating other disorders. IBS-C is very similar to chronic constipation but is clinically distinguished by its significant pain component.

Based on reports in the literature regarding the prevalence of IBS in the U.S. population and the percentage of individuals who have IBS-C as opposed to other forms of IBS, Ardelyx estimates that approximately 1.4 percent of the U.S. population has IBS-C, or about 4.4 million individuals. Of those, approximately 1.0 million patients have been diagnosed with IBS-C. Additionally, there are about 6.6 million IBS-C patients in Europe and about 3.4 million in Japan.

Tenapanor

Tenapanor (also known as RDX5791 and AZD1722) is a minimally-absorbed small molecule inhibitor of NHE3, a transporter of sodium in the gastrointestinal tract.  Orally administered tenapanor has been shown in clinical trials to reduce the intestinal absorption of both dietary sodium and phosphorus.  A total of 12 clinical trials of tenapanor have been completed or are ongoing, including over 830 subjects who have been administered tenapanor to date.  In addition to the IBS-C Phase 2b clinical trial, Ardelyx and AstraZeneca are evaluating tenapanor in two other indications:

• ESRD patients on hemodialysis to treat hyperphosphatemia: Phase 2b randomized, double-blind, placebo-controlled clinical trial in 150 ESRD patients to evaluate the effects of tenapanor on serum phosphorus. Enrollment is ongoing and the results of this clinical trial are expected in the first half of 2015.
• Stage 3 CKD patients with type 2 diabetes mellitus, the presence of the protein albumin in the urine, or albuminuria, and high blood pressure: Phase 2a randomized, double-blind, placebo-controlled clinical trial in 140 patients to evaluate the effects of tenapanor on kidney function and fluid overload. Enrollment is ongoing and the results of this clinical trial are expected in the second half of 2015.

Conference Call / Web Cast Information

Ardelyx management will host a live conference call and webcast today at 8:00 a.m. Eastern Time to discuss the Phase 2b IBS-C results.

The live webcast and a replay may be accessed by visiting Ardelyx’s website at http://ir.ardelyx.com/

Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (855) 296-9612 (U.S.) or (920) 663-6277 (international) to listen to the live conference call. The conference ID number for the live call is 13895374. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 13895374. The telephone replay will be available until October 8, 2014.

About Ardelyx, Inc.

Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, non-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. The Company has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor.

Ardelyx formed a collaborative partnership with AstraZeneca in October 2012 to develop and commercialize tenapanor. In addition to tenapanor, the Company has discovered small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in ESRD, a program licensed to Sanofi, and independently is advancing several additional research programs focused in cardio-renal, gastrointestinal and metabolic diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx’s website at www.ardelyx.com.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including statements regarding the potential for tenapanor in treating IBS-C patients, the potential of tenapanor in treating the renal indications for which it is currently being evaluated, the availability and timing of data from ongoing tenapanor clinical trials, and the potential of our drug discovery and design platform.    Such forward-looking statements involve substantial risks and uncertainties that could cause the development of tenapanor, or Ardelyx’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.   Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process, Ardelyx’s reliance upon AstraZeneca for the development of tenapanor, and AstraZeneca’s right under the license agreement to choose which indication or indications for which tenapanor will be developed. Ardelyx undertakes no obligation to update or revise any forward-looking statements.   For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx’s business in general, please refer to Ardelyx’s second quarter report filed on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2014.

(FBCD) nitial Purchase Order for 7,000 Units and Expect Delivery by Mid October

Company Is Funding COCO-AMO as the LOVE “Leave In Conditioner”, HYDRATE Shampoo and PURE Sulfate Free Shampoo Are Launch Within a Few Weeks

(VSTR) Buys Mobile Content Delivery Business

White Plains, NY / October 01, 2014 / Valuesetters, Inc. (OTC Pink: VSTR) announced that it has purchased the mobile content delivery platform and operations of TelcoSoftware.com Corp., a cloud-based over-the-top (OTT) content delivery business.

Valuesetter’s Chief Executive Officer, Manny Teixeira, noted, “TelcoSoftware has been providing an innovative technology for more than 10 years, and is the vendor behind our V-Star app that we sell on Google Play. Instead of being a customer of TelcoSoftware, we decided it was in our best interest to own their technology and use our marketing dollars to increase OTT revenues. With our ownership of this mobile content platform, we are now capable of distributing music, movies, text, voice and advertising.”

Teixeira continued, “We believe that OTT delivery is critical to attracting and keeping subscribers. Offering multiple content options is becoming increasingly important as consumers utilize their devices for games, video, audio and other media needs. We project an increasing demand for functions created by cloud solutions, and we are very excited that we are now a cloud-based mobile app and media company.”

In order to complete the purchase, the majority shareholder of Valuesetters paid 40 million shares of common stock to TelcoSoftware.com Corp., and Valuesetters then purchased the business from its majority shareholder for a $1 million note.

About Valuesetters:

Valuesetters is an Internet-based company that seeks free subscribers and revenue-generating subscribers. Valuesetters operates on an automated basis with the belief that Internet operations, customer sign-ups, sales and game playing should occur without human intervention so that it can quickly expand in the event the number of subscribers begins to rapidly grow on a viral basis. Its focus is on the digital delivery of games, apps, movies and music. Research from Parks Associates shows that 55% of broadband households subscribe to OTT services.

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Contact:

Manuel Teixeria, CEO
203-525-0450
mannyteixeira@gmail.com

(PTQMF) Announces Bridge Loan, Board Changes, and Financial Year End Amendment

Petaquilla Minerals Ltd.
Phone: (604) 694-0021 Fax: (604) 694-0063
Toll free: 1-877-694-0021
www.petaquilla.com

(SNOVF) Update for Eagle #1 Well

Super Nova Petroleum Corp.
Wolf Wiese
CEO
604-336-1490
604-221-8936

Super Nova Petroleum Corp.
Mike Poulin
Corporate Communications
604-221-8936
mike@supernovaminerals.com

(NETE) MissionIR Exclusive Audio Interview With Net Element CEO Oleg Firer